When the Most Potent Combination of Antibiotics Selects for the Greatest Bacterial Load: The Smile-Frown Transition

PLoS Biology

Volumn 11, Issue 4, 2013, Pages

  Pena Miller, Rafael ^a   Laehnemann, David ^b   Jansen, Gunther ^b   Fuentes Hernandez, Ayari ^a   Rosenstiel, Philip ^b   Schulenburg, Hinrich ^b   Beardmore, Robert ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; ERYTHROMYCIN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIUM CULTURE; CALIBRATION; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG POTENTIATION; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC MANIPULATION; MATHEMATICAL MODEL; MONOTHERAPY; NONHUMAN; OPERON; PREDICTION;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL LOAD; COMPUTER SIMULATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI K12; EVOLUTION, MOLECULAR; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, BIOLOGICAL; OPERON; POLYMORPHISM, SINGLE NUCLEOTIDE;

BACTERIA (MICROORGANISMS);

EID: 84876955225     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001540     Document Type: Article

References (50)

1. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, et al. (2011) Systematic exploration of synergistic drug pairs. Mol Syst Biol 7: 544.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12.
3. Payne DJ, Gwynn MN, Holmes DJ, Pompliano L, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
4. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, et al. (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104: 9451-9456.
5. Read AF, Huijben S, (2009) Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl 2: 40-51.
6. Ehrlich P, (1913) Address in pathology on chemotherapeutics. Lancet pp. 445-451.
7. Price CW, Randall WA, (1949) Studies of the combined action of antibiotics and sulfonamides. Am J Public Health Nations Health 39: 340-344.
8. Loewe S, (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3: 285-290.
9. Holm SE, (1986) Interaction between β-lactam and other antibiotics. Rev Infect Dis 8: S305-S314.
10. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK, (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137: 381-433.
11. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, et al. (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227-253.
12. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK, (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466.
13. Choi H, Lee DG, (2012) Synergistic effect of antimicrobial peptide arenicin-1 in combination with antibiotics against pathogenic bacteria. Res Microbiol 163: 479-486.
14. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R, (2008) Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A 105: 13977-13981.
15. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R, (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7: 460-466.
16. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotech 27: 659-666.
17. Greco WR, Bravo G, Parsons JC, (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331-385.
18. Read AF, Day T, Huijben S, (2011) The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci U S A 108 (Suppl 2): 10871-10877.
19. Odenholt I, (2001) Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 17: 1-8.
20. Cars O, Odenholt-Tornqvist I, (1993) The post-antibiotic sub-mic effect in vitro and in vivo. J Antimicrob Chemother 31 (Suppl D): 159-166.
21. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, et al. (2008) Tissue concentrations: do we ever learn? Journal of Antimicrobial Chemotherapy 61: 235-237.
22. Olofsson SK, Cars O, (2007) Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 45 Suppl 2: S129-36.
23. Tsaganos T, Skiadas I, Koutoukas P, Adamis T, Baxevanos N, et al. (2008) Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant staphylococcus aureus endocarditis. Journal of Antimicrobial Chemotherapy 62: 381-383.
24. Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, et al. (2011) Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 7: e1002158.
25. Hastings I, D'Alessandro U, (2000) Modelling a predictable disaster: The rise and spread of drug-resistant malaria. Parasitology Today 16: 340-347.
26. Palmer AC, Angelino E, Kishony R, (2010) Chemical decay of an antibiotic inverts selection for resistance. Nat Chem Biol 6: 244-244.
27. Alekshun MN, Levy SB, (1999) The mar regulon: multiple resistance to antibiotics and other toxic chemicals. Trends Microbiol 7: 410-413.
28. Eicher T, Cha HJ, Seeger MA, Brandstatter L, El-Delik J, et al. (2012) Transport of drugs by the multidrug transporter acrb involves an access and a deep binding pocket that are separated by a switch-loop. Proc Natl Acad Sci U S A 109: 5687-5692.
29. Sandegren L, Andersson DI, (2009) Bacterial gene amplification: implications for the evolution of antibiotic resistance. Nat Rev Microbiol 7: 578-588.
30. Andersson DI, (2005) The ways in which bacteria resist antibiotics. Int J Risk Saf Med 17: 111-116.
31. George AM, Levy SB, (1983) Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline. J Bacteriol 155: 531-540.
32. Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A, (2009) Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother 53: 2266-2273.
33. Jackson RC, (1993) Amphibolic drug combinations: the design of selective antimetabolite protocols based upon the kinetic properties of multienzyme systems. Cancer Res 53: 3998-4003.
34. Harvey R, (1978) Interaction of two inhibitors which act on different enzymes of a metabolic pathway. J Theor Biol 74: 411-437.
35. Bayer AS, Morrison JO, (1984) Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and-resistant Staphylococcus aureus. Antimicrob Agents Chemother 26: 220-223.
36. Rand KH, Houck HJ, Brown P, Bennett D, (1993) Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother 37: 613-615.
37. White RL, Burgess DS, Manduru M, Bosso JA, (1996) Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40: 1914-1918.
38. Rice LB, (2007) Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve Clin J Med 74 Suppl 4: S12-20.
39. Li XZ, Nikaido H, (2009) Efflux-mediated drug resistance in bacteria: an update. Drugs 69: 1555-1623.
40. Gibbons S, Udo EE, (2000) The effect of reserpine, a modulator of multidrug efflux pumps, on the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) possessing the tet(k) determinant. Phytother Res 14: 139-140.
41. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, et al. (2011) Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 184: 269-276.
42. Deresinski S, (2009) Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 49: 1072-1079.
43. Yeh P, Tschumi AI, Kishony R, (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38: 489-494.
44. Sarkar SK, Chowdhury C, Ghosh AS, (2010) Deletion of penicillin-binding protein 5 (PBP5) sensitises Escherichia coli cells to beta-lactam agents. Int J Antimicrob Agents 35: 244-249.
45. Fujisaki S, Ohnuma S, Horiuchi T, Takahashi I, Tsukui S, et al. (1996) Cloning of a gene from Escherichia coli that confers resistance to fosmidomycin as a consequence of amplification. Gene 175: 83-87.
46. Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE, (2008) Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets 9: 816-819.
47. Odds FC, (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1.
48. Desbiolles N, Piroth L, Lequeu C, Neuwirth C, Portier H, et al. (2001) Fractional maximal effect method for in vitro synergy between amoxicillin and ceftriaxone and between vancomycin and ceftriaxone against Enterococcus faecalis and penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 45: 3328-3333.
49. Lambert R, Johnston M, Hanlon G, Denyer S, (2003) Theory of antimicrobial combinations: biocide mixtures - synergy or addition? J Appl Microbiol 94: 747-759.
50. D'Errico J (2012). Matlab central file exchange: Surface fitting using gridfit. URL http://www.mathworks.com/matlabcentral/fileexchange/8998.